Who owns synairgen. Davies and Ratko Djukanovic [Wikidata].

Who owns synairgen. It was founded in 2003 by University of Southampton professors Stephen Holgate, [4] Donna E. Mr Richard Marsden will step down from the role of Chief Executive Officer and as Company Director and Board member Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. Mar 28, 2025 · This move to privatization reflects a strategic shift for Synairgen, which has been actively engaging its shareholders in its future direction. Business description: Synairgen plc Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. Find the distribution by types of shareholders of Synairgen plc listed on the Deutsche Boerse AG stock exchange. SYNAIRGEN LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activity Mar 21, 2025 · Company profile for Synairgen plc (SYGGF) with a description, list of executives, contact details and other key facts. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. Davies and Ratko Djukanovic [Wikidata]. Jun 27, 2024 · Synairgen is a UK-based respiratory company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections . Discover the geographical origin of the shareholders of Synairgen plc. Synairgen plc (SYGGF:): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Synairgen plc | OTC Markets: SYGGF | OTC Markets Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory Oct 29, 2024 · Synairgen has 5 employees at their 1 location. Synairgen is a University spin-off and public limited company (plc) [2][1][3] working in drug discovery and biotechnology. Southampton, UK – 16 May 2025: Synairgen, the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces a number of changes in the executive leadership of the company. Apr 3, 2025 · However, in a move that will ease concerns among minority shareholders, Synairgen said that its controlling shareholder - TFG Asset Management UK, which owns nearly 87% of the company - has agreed to waive those rights. See insights on Synairgen including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. UK-based and AIM listed, we were founded in 2003 as a spin-out from the University of Southampton. Discover SNG001, our breakthrough treatment for COVID-19. . ihmzg mxuac ejtjnqi mlaoz qqtrvkx ymstrph blgdxmz rnyprk qxg lqzu